ClinicalTrials.gg
WithdrawnNCT03265951DORMIUpdated Apr 9, 2021

Ramelteon for Complex Insomnia in Veterans With PTSD

A Phase 4 interventional study of Ramelteon and Usual Care in Insomnia, sponsored by State University of New York at Buffalo. Withdrawn at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-04-09.

Sponsored by State University of New York at Buffalo · Phase 4, Interventional, and Treatment

How we know

Why this study was withdrawn
Lack of response

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 36 studies testing ramelteon in Sleep Initiation and Maintenance Disorders — 1 open to participants now, 1 under way, 1 of them phase 3. ramelteon · Sleep Initiation and Maintenance Disorders.

Enrollment
35th of 36
0 · median 65
Started
2018
with 1 other
Phase 4
13 of 36
none open now
Registered
33rd of 36
by date

Among the 36 studies testing ramelteon in Sleep Initiation and Maintenance Disorders, this one is the 35th largest by enrollment, is one of 2 that started in 2018, is one of 13 in phase 4, and was the 33rd registered.

Sleep Initiation and Maintenance Disorders

2,732 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 733 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

1 of the 36 studies testing ramelteon in Sleep Initiation and Maintenance Disorders is open now. Recruiting first, the newest first:

About ramelteon

ramelteon: first FDA approval 2005 (ROZEREM). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 392 Sleep Initiation and Maintenance Disorders studies recruiting now, 155 (40%) set no upper age limit and 207 (53%) stop at 75 or younger; 59 take children under 18; 110 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing ramelteon in Sleep Initiation and Maintenance Disorders, or all of them as a file.
02

Study summary

Obstructive sleep apnea is commonly reported in Veterans with post-traumatic stress disorder, which can potentiate symptoms of anxiety and depression, daytime symptoms and worsen nightmares. Continuous positive airway pressure is the most effective therapy but adherence to treatment is suboptimal. The overarching theme of the proposal is to compare usual care to Ramelteon, in a randomized, clinical trial, investigating the effectiveness of physiological versus pharmacological intervention on sleep quality of life, insomnia severity and CPAP adherence.

Read the detailed description

Despite the overall improvement in PTSD symptomatology with CPAP therapy, adherence to CPAP is far worse in Veterans with PTSD (41%) compared to the general population with OSA (70%). Among the factors associated with CPAP non-adherence is the coexistence of insomnia. Complex insomnia defined as the coexistence of comorbid insomnia ans OSA is a frequent diagnosis in military personnel with combat exposure. Similar to prior reports of patients with OSA without PTSD, comorbid insomnia can create a barrier to CPAP therapy. Ramelteon (TAK-375), approved by the Food and Drug Administration for the treatment of insomnia with sleep onset abnormalities, is a neurohormone that functions as a melatonin receptor agonist targeting the MT1 and MT2 receptors located in the suprachiasmatic nucleus of the hypothalamus which regulates the circadian rhythm of the 24-hour sleep-wake cycle.The goal is to test the hypothesis that the administration of insomnia therapy-ramelteon- significantly improves treatment outcomes in Veterans with PTSD and complex insomnia compared with placebo.

03

Conditions studied

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years and ≤70 years old
  • Diagnosis of PTSD as determined by the intake conducted through the PTSD Clinic or the Mental Health Clinic
  • Documented obstructive sleep apnea by polysomnography (AHI≥5 or more/hour)
  • CPAP non adherence defined as less than 70% of nights with >4h CPAP use despite addressing modifiable barriers for CPAP adherence
  • Psychotherapeutic treatment stable for at least 4 weeks prior to randomization
  • Capable of giving

Exclusion criteria

Exclusion Criteria:

  • Medical:

    • Acute or unstable chronic medical illness
    • History of narcolepsy and/or cataplexy Use of any of these medications: Fluvoxamine, fluconazole (Diflucan), itraconazole (Sporanox), and ketoconazole (Nizoral); cimetidine (Tagamet); clarithromycin (Biaxin); fluoroquinolones including ciprofloxacin, levofloxacin (Levaquin), moxifloxacin (Avelox), norfloxacin (Noroxin), ofloxacin (Floxin), others; protease inhibitors including indinavir (Crixivan), nelfinavir (Viracept), and ritonavir (Norvir, in Kaletra); nefazodone; rifampin
    • Treatment for seizure disorders
    • Pregnant or lactating
    • History of hepatic impairment
    • History of , intolerance, or to ramelteon
    • Unwilling to try or use CPAP

Psychiatric/Behavioral:

  • Diagnosis of current schizophrenia or schizoaffective disorder
  • Diagnosis of a substance dependence/abuse disorder in the past year
  • Severe psychiatric instability or severe situational life crises, including evidence of being actively suicidal or homicidal, or any behavior which poses an immediate danger to patient or others
  • Diagnosis of bipolar disorder
  • Consumption of more than two alcoholic beverages per night
  • Receiving behavioral or pharmacological treatment for insomnia
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Active comparator
    Ramelteon

    Ramelteon 8 mg po at bedtime

    Drug: Ramelteon

  • Placebo comparator
    Usual care

    education brochure about sleep hygiene

    Other: Usual Care

Interventions

  • 8 mg once daily administered within 30 minutes of bedtime

    Also known as: Rozerem

  • OtherUsual Care

    education brochure about sleep hygiene

06

What researchers measure

Primary outcomes

  1. Pittsburgh Sleep Quality Index

    Quality of life

    Time frame: 12 weeks post randomization

Secondary outcomes

  1. PCL-5

    PTSD Checklist

    Time frame: 12 weeks post randomization

  2. ISI

    Insomnia Severity Index

    Time frame: 12 weeks post randomization

  3. CPAP adherence

    CPAP adherence

    Time frame: 12 weeks post randomization

07

Study locations

1 site
  • Veterans Affairs Medical Center in Buffalo
    Buffalo, New York 14215, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2018 to primary completion in Sep 2019, 20 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2017
First posted
Aug 29, 2017
StartActual
Jan 1, 2018
Primary completionActual
Sep 30, 2019
CompletionActual
Jun 30, 2020
Last update
Apr 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03265951
Collaborators
The VA Western New York Healthcare System
Responsible party
Ali El Solh (Principal Investigator, State University of New York at Buffalo) — Principal investigator
First posted
Aug 29, 2017
Start date
Jan 1, 2018
Primary completion
Sep 30, 2019
Completion
Jun 30, 2020
Last update
Apr 9, 2021

Study contacts

Ali El Solh, MD
principal investigator · The VA Western New York

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ramelteon

Start the discussion